CDK4 and breast carcinoma: Given the previously described sensitivity of HR-positive breast cancer models to CDK4/6 inhibition in vitro [11], we tested ribociclib and standard-of-care endocrine therapies in a breast cancer PDX model (HBCx-34) that was grown in the presence of estrogen supplementation and had shown response to endocrine therapies in other studies [45].